Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors

• Published in: Journal of clinical pharmacology 2023-07, Vol.63 (7), p.817-829
• Main Authors: Hwang, Michael, Fan, Chunling, Yue, Mun Sang, Zhou, Diansong, Paturel, Carine, Andre, Pascale, Cheng, Lin‐Yang, Mitchell, Patrick, Kourtesis, Panagiotis, Ruscica, Dario, Das, Mayukh, Morsli, Nassim, Ren, Song, Gibbs, Megan, Phipps, Alex, Song, Xuyang
• Format: Article
• Language: English
• Subjects: Body weight; clinical pharmacology (CPH); Clinical trials; Head and neck carcinoma; Immune checkpoint inhibitors; Immune clearance; Immunoglobulin G4; Immunoglobulins; immuno‐oncology; monalizumab; Monoclonal antibodies; NKG2A; Pharmacokinetics; pharmacometrics; Solid tumors; Squamous cell carcinoma; Statistical analysis
• ISSN: 0091-2700; 1552-4604
• DOI: 10.1002/jcph.2220

Monalizumab is a novel, first‐in‐class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors. The objectives of this analysis were to develop a population pharmacokinetic (PK) model of monalizumab, evaluate the impact of clinically relevant covariates on monalizumab PK, and provide dose justification for clinical trials. We developed a monalizumab population PK model to characterize the PK properties of monalizumab in patients with advanced solid tumors or head and neck squamous cell carcinoma. Data from clinical studies D419NC00001 (NCT02671435) and IPH2201‐203 (NCT02643550) were pooled for the analysis, resulting in a data set of 3066 PK samples derived from 507 subjects. The PK of monalizumab were reasonably described by a 2‐compartment model with first‐order elimination. Monalizumab generally exhibited linear PK over a dose range of 22.5‐750 mg or 10 mg/kg every 2 weeks. The estimate of clearance was ≈0.255 L/day, and apparent volume of distribution was 6.36 L for a typical individual, consistent with previous findings for endogenous immunoglobulin Gs and other therapeutic monoclonal antibodies. Baseline albumin and body weight were identified as significant covariates of clearance; body weight, sex, and smoking status had a significant impact on volume of distribution; and none of these covariates had impact on peripheral volume of distribution. Although these covariates were identified as statistically significant, they are considered to be not clinically meaningful, as changes in monalizumab exposure were